Exelixis And Insilico Medicine Enter Into Exclusive Global License Agreement For ISM3091; Insilico Grants Exelixis Exclusive Worldwide License To Develop And Commercialize ISM3091 For Upfront Payment Of $80M
Portfolio Pulse from Bill Haddad
Exelixis and Insilico Medicine have entered into an exclusive global license agreement for ISM3091. Insilico has granted Exelixis an exclusive worldwide license to develop and commercialize ISM3091 for an upfront payment of $80 million.
September 12, 2023 | 12:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Exelixis has acquired an exclusive global license to develop and commercialize ISM3091 from Insilico Medicine for $80 million.
The news of Exelixis acquiring an exclusive global license for ISM3091 is directly related to the company and is likely to have a positive impact on its stock in the short term. The $80 million upfront payment indicates a significant investment and confidence in the potential of ISM3091. This could lead to increased investor confidence in Exelixis, potentially driving up the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100